Rex Fang & Innovation Equity Premium Income ETF vs Zimmer Biomet Holdings Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.87, while Zimmer Biomet Holdings Inc trades at $96.56 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $107.71 |
52-Week Low | $37.98 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.88 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The ETF generates substantial income through weekly dividend distributions averaging $0.20-0.21 per share, funded by its covered call strategy on concentrated AI and tech holdings. Recent news highlights the fund's transition to weekly distributions and ongoing discussions about its aggressive income approach.
The high-yield strategy presents income opportunities but carries significant risk from NAV erosion during market downturns. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of 25% yields and concentrated exposure to volatile tech names warrant cautious positioning. The covered call approach limits upside potential while providing consistent cash flow.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →